StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) company profile

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$47.29−3.73 (-7.31%)

Close on Nov 17, 2026Market cap $1.41BP/E –Yield –

About GeneDx

Services-Health Services, SIC 8000

GeneDx Holdings Corp. operates as a genomics and diagnostics company focused on genetic testing services and solutions. Its offerings include diagnostic test products and diagnostic testing kits and materials, alongside technology rights and related services. The company categorizes its business operations under the GeneDx segment as well as an all other segments classification, serving third-party insurance payors, institutional customers, and self-pay individuals.

The company maintains operational activities across domestic and international locations, including operations or jurisdictions in California, Florida, Maryland, North Carolina, Pennsylvania, Canada, and Iceland. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, with its principal executive offices located at 333 Ludlow Street.

Summary of the business section of GeneDx's latest annual report, written by StockData.

Company profile

Company

Legal name
GeneDx Holdings Corp.
Headquarters
Stamford, CT
Address
333 Ludlow Street, North Tower, 6th Floor 06902
Phone
(888) 729-1206
Website
genedx.com
Employees
1,300, Dec 31, 2025
Industry
Services-Health Services
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
ERNST & YOUNG LLP, New York, New York

Stock & identifiers

Ticker
WGS
Former tickers
SMFR until Jan 12, 2023; CMLF until Aug 16, 2021
Exchange
Nasdaq
IPO date
Sep 3, 2020
Shares outstanding
30M, Jul 27, 2026
Public float
$1.66B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-33 reverse, May 4, 2023
SEC CIK
1818331
CUSIP
81663L101
ISIN
US81663L1017
FIGI
BBG00XDHY5P9
Share class FIGI
BBG00XDHY5R7
EIN
85-1966622

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Katherine StuelandCHIEF EXECUTIVE OFFICER, Director115,476
Kevin FeeleyCHIEF FINANCIAL OFFICER48,035
Mark A. GardnerPresident–
Bryan DechairoChief Operating Officer2,723
Thomas FuchsDirector1,146
Emily M. LeproustDirector24,852
Keith A. MeisterDirector4,808,275
Joshua RuchDirector189,566
Richard C. Pfenniger JrDirector45,082
Eli CasdinDirector4,083,648
Jason RyanDirector118,764
Casdin Partners GP, LLCDirector–
Casdin Partners Master Fund, L.P.Director3,880,072
Casdin Capital, LLCDirector3,859,555
Management LP CorvexDirector3,374,334

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.55M$43.35M$4.14M$1494$139
FY2024$4.42M$51.51M$895.54K$883$104
FY2023$3.50M$545.95K$1.24M$32$105

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Katherine Stueland
Chief Executive Officer
$715.87K–$11.74M$1.08M$17.25K$13.55M+206%
Kevin Feeley
Chief Financial Officer
$500.60K–$3.76M$414.15K$17.25K$4.69M+247%
Bryan Dechairo
Chief Operating Officer
$436.15K$75.00K$2.70M$371.25K–$3.58M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Sep 3, 2020
Offer price
$10.00
Exchange
Nasdaq
First trading day
Nov 4, 2020
First-day close
$9.80-2.0%
Lock-up ends (est.)
May 3, 2021

“Each unit has an offering price of $10.00 and consists of one share of Class A common stock and one -third of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Our team of nearly 1,300 individuals are champions of not only our organization, but our patients, providers and partners.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 21, 2026DelistingNotice of delisting from exchange (Form 25)
Jan 5, 2023Name changeName changed from Sema4 Holdings Corp. to GeneDx Holdings Corp.
Dec 30, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 2, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 31, 2022Merger voteDefinitive merger proxy statement
Aug 16, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 16, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 28, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 28, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 23, 2021DelistingNotice of delisting from exchange (Form 25)
Jul 21, 2021Name changeName changed from CM Life Sciences, Inc. to Sema4 Holdings Corp.
Jul 2, 2021Merger voteDefinitive merger proxy statement
May 18, 2021Late filingNotification of late filing
Sep 3, 2020IPOInitial public offering priced (424B4 prospectus)
Aug 31, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?